Sagimet Biosciences Inc.
NASDAQ:SGMTBiotechnology
+$0.09 today
- Market cap
- $711.15M
- Beta
- 3.44
- P/E (TTM)
- -5.0
- EPS (TTM)
- -$1.34
Volume 0.93M
Average 1.49M
SGMT Total Equity
Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.
Sagimet Biosciences Inc.NASDAQ: SGMT
Total Equity · Q1 FY2026 · quarter ended Mar 2026
Total equity falls 26.3% from a year ago
Total equity stood at $102.46M at the end of Q1 FY2026, down 26.3% from a year earlier and down 8.0% from the prior quarter.
Context
- Total equity amounted to 95.1% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Total equity increased in 2 of the last 3 fiscal years.
What to watch
Whether total equity keeps falling in the next quarterly balance sheet after a -26.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Equity history
USD · from the balance sheet
- Latest · FY2025
- 111.38M USD
- Year-over-year change
- -28.5%
| Period | Period end | Total Equity | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 111.38M | -28.5% |
| FY2024 | 2024-12-31 | 155.81M | +71.1% |
| FY2023 | 2023-12-31 | 91.07M | +148.7% |
| FY2022 | 2022-12-31 | (186.95M) | -18.1% |
| FY2021 | 2021-12-31 | (158.26M) | — |
Total Equity vs competitors
How SGMT compares with its peers on the latest reported figures
- SGMT's Mar 2026 total equity of $102.46M is the 8th highest of the 11 companies compared; the peer median is $194.99M.
- Its year-over-year change of -26.3% is the 7th highest of 11, against a peer median of -21.0%.
- Total equity amounts to 95.1% of total assets for SGMT, versus a peer median of 80.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $206.52B | +493455.8% | +25.8% | 96.1% | |
| Mar 2026 | $270.85M | -35.1% | +12.9% | 80.7% | |
| Mar 2026 | $233.71M | -43.1% | -24.5% | 87.5% | |
ZURAZura Bio Limited | Mar 2026 | $216.9M | +43.3% | — | 94.9% |
| Mar 2026 | $198.61M | +632.0% | +35.7% | 84.3% | |
| Mar 2026 | $191.36M | -18.1% | -7.5% | 78.0% | |
| Mar 2026 | $173.67M | -36.3% | +49.2% | 79.2% | |
SGMTSagimet Biosciences Inc. | Mar 2026 | $102.46M | -26.3% | — | 95.1% |
| Mar 2026 | $11.62M | -67.7% | -70.2% | 10.5% | |
| Mar 2026 | $10.68M | +3.9% | +37.4% | 32.3% | |
| Mar 2026 | -$76.41M | -23.9% | — | 34.4% | |
| Peer median (excluding SGMT) | $194.99M | -21.0% | +19.3% | 80.0% | |
Competitors are the stored peer set for SGMT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Sagimet Biosciences Inc.
NASDAQ:SGMT
Intrinsic Alpha fair value
Locked
Current Price
$10.11
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.